Silexion Therapeutics Corp. SLXN stock is trading higher on Tuesday with a strong session volume of 36.4 million versus the average volume of 2.
65 as per data from Benzinga Pro . Silexion released new preclinical findings for SIL-204, its second-generation siRNA candidate, following the optimization of its extended-release formulation . SIL-204 demonstrated substantial tumor reduction in human pancreatic tumor cell lines with the KRAS G12D (Panc -1) mutations using the oncogene silencing approach with siRNA.
Previous studies showed this effect using unformulated siRNA with daily injections. The new studies further show this effect with a single administration of SIL-204 encapsulated in an extended-release formulation. Moreover, histopathological examination of treated tumors showed a very high induction of tumor necrosis.
Also Read: Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise . The transition from PLGA depot rods to PLGA microparticles (MPs) has resulted in a superior extended-release profile, enhancing the therapeutic potential. We now report in vivo results indicating that our new modified PLGA-microparticle formulation has superior properties over previous extended-release formulations (Loder).
Silexion plans to initiate toxicology studies with SIL-204 within the upcoming months and advance it into Phase 2/3 trials in the first half of 2026, focusing initially on locally advanced pancreatic cancer (LAPC), which has a n.